Eckert & Ziegler Strahlen- und Medizintechnik AG

  • WKN: 565970
  • ISIN: DE0005659700
  • Land: Deutschland

Nachricht vom 05.11.2021 | 14:37

Eckert & Ziegler Acquires Property for Radiopharmaceutical Production Site in China

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Expansion
05.11.2021 / 14:37
The issuer is solely responsible for the content of this announcement.

Berlin, 5 November 2021. Eckert & Ziegler AG (ISIN DE0005659700), a global specialist for isotope applications in medicine and industry has acquired an approximately 7,000 m² property with an expansion option for the building of its Chinese production facility in Jintan (PR China). The purchase was made through a public tender process. The location in the Jiangsu province near Shanghai will be used to build production facilities for radiopharmaceuticals and radioisotopes as well as Eckert & Ziegler's administrative headquarters for the Chinese market. In the medium term, other divisions of the Eckert & Ziegler Group as well as service facilities are also to be located there and third parties are to be offered the infrastructure for joint use. The business in China is managed by the wholly owned subsidiary Qi Kang Medical Technology (Changzhou) Co., Ltd. (QKM).

Construction will start at the beginning of next year. Completion of the building and operational readiness are to take place in stages. By end 2027, the investment volume, including land, building, technical equipment, and intangible assets, will amount to up to 50 million EUR. If the project can be implemented as planned, radiopharmaceutical contract production for the international pharmaceutical industry as well as the sale of the company's own products will take place at the new site in Jintan. Eckert & Ziegler will thus also offer a one-stop service in Asia for a wide range of radiopharmaceutical services under "GMP and cGMP conditions".

"Cancer is one of the most common causes of death in China," explained Dr. Andreas Eckert, founder and CEO of Eckert & Ziegler. "Treatment methods based on precision oncology should also be available to patients in China in the future. As a globally active supplier for oncology specialty companies, it is important for us to be represented in China with a licensed production site and a strong local team. With the property acquisition in Jintan, we are well prepared for the expected growth in China."

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com



05.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

net digital, der digitale und mobile Payment-Spezialist

Die net digital AG agiert mit ihren digitalen und mobilen Paymentlösungen und den hierzu ergänzenden Diensten (z. B. Abo-Management und zahlungsbezogene KI-Lösungen) im multimilliarden-schweren Paymentmarkt. Basierend auf der vielversprechenden Wachstumsstrategie und der guten Marktpositionierung, sollte es dem net digital-Konzern gelingen, ab dem Jahr 2022 ein nachhaltiges dynamisches Wachstum zu erreichen. Parallel hierzu rechnen wir aufgrund des sehr skalierbaren Geschäftsmodells (Plattform-Ansatz) mit einer überproportionalen Ergebnisverbesserung. Bei dem von uns ermittelten Kursziel von 20,60 € vergeben wir das Rating KAUFEN.

News im Fokus

Henkel AG & Co. KGaA: Umfassende Maßnahmen, um Wachstumsagenda von Henkel auf nächste Stufe zu heben

28. Januar 2022, 09:08

Aktueller Webcast

HelloFresh SE

2022 Governance Roadshow Presentation

28. Januar 2022

Aktuelle Research-Studie

va-Q-tec AG

Original-Research: va-Q-tec AG (von Montega AG): Kaufen

28. Januar 2022